REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1120 participants.
Also called NCT07410117
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,120 participants
- Sponsor
- Registry
-
NCT07410117 -
2024-519298-21-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Georgia, Japan
- Registry status
- Recruiting
Technical summary
Registry record NCT07410117. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-09 (actual); primary completion 2030-01-23 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
- Acronym
- ROXI-CAT-I
- Condition
- Cancer-Associated Thrombosis (CAT)
- Intervention (Drug)
- REGN7508
- Intervention (Drug)
- Placebo
- Lead sponsor
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct07410117- Content hash
b3b2b5331150755583558b16f5f644b73e50ec2a225649ae8d17bf52d3158213